Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.

On the 834-patient trial's primary

Read the full 473 word article

User Sign In